11 月 21 日，以 " 智领健康未来 " 为主题的 2025 华夏大健康产业发展暨康复服务大会在北京召开。作为连续四届引领行业风向的标杆盛会，科技与创新 始终是贯穿全程的灵魂主线，而医疗健康企业在环境、社会及治理方面的表现同样被社会各界关注。 万得 ESG高级分析师 受邀发表了主题演讲，详细介绍了蒲公英指数的构建背景、评估体系及市场表现，强调该指数为医疗健康行业可持续发展提供了重 要参考。 万得首先介绍了 Wind 万得的业务背景： "Wind 是一家专业化的信息服务机构，为金融领域开发了信息检索、数据提取及组合管理等专业工具，是国内外 机构投资者的重要合作伙伴。 " 她特别指出， Wind 构建的独立 ESG 评级体系已广泛应用于政策研究、金融决策和企业实践当中，例如国务院发展研究 中心发布的报告及可持续挂钩债券发行实践。 蒲公英指数亦是 Wind ESG 评级体系的一次创新性应用。该指数由华夏时报大健康研究院与万得联合研发，从医疗健康领域 A 股 495 家公司中精选前 50 家组成 " 蒲公英 50 指数 " ，港股 262 家公司中精选 30 家组成 " 蒲公英 30 指数 " ，每月根据 ESG ...

Core Viewpoint - The 2025 Huaxia Health Industry Development and Rehabilitation Service Conference emphasizes the importance of technology and innovation in the healthcare sector, alongside the growing focus on environmental, social, and governance (ESG) performance of healthcare companies [2][3]. Group 1: ESG Rating System - The Dandelion Index, developed by Huaxia Times Health Research Institute and Wind, selects the top 50 companies from 495 A-share healthcare companies and 30 from 262 Hong Kong healthcare companies, adjusting the components monthly based on ESG scores [3][4]. - The ESG rating system evaluates companies on long-term management practices across environmental, social, and governance dimensions, incorporating over 500 indicators and 28 topics, with a focus on industry-specific issues [4][7]. Group 2: Index Performance - The Dandelion Index shows superior performance, with the Dandelion 50 Index rising approximately 29% year-to-date, outperforming the CSI 300 and healthcare industry indices by about 35 percentage points, with an annualized return of around 10% [8][11]. - The Dandelion 30 Index has achieved a year-to-date increase of 104%, significantly surpassing the Hong Kong healthcare industry index and the Hang Seng Index, with a five-year cumulative return of 63% [11][12]. Group 3: Company Ratings - 80 companies with excellent ESG performance are included in the Dandelion Index, with Haier Biomedical and Yinkang Life receiving the highest AAA rating [7]. - In the Dandelion 50 Index, 62% of companies are rated AA, while 34% are rated A; the Dandelion 30 Index has 77% rated AA, with no low-rated companies, contrasting with over 69% of the healthcare industry having low ratings [7][8]. Group 4: Call to Action - The conference encourages more companies to engage in ESG practices and register on the Wind ESG issuer communication platform for rating feedback, aiming to promote sustainable development in the industry [14].

Core Viewpoint - Haier Biomedical plans to cancel 1.4596 million repurchased shares to optimize its equity structure, reflecting its commitment to shareholder returns through a "repurchase + dividend" mechanism since its IPO in 2019 [1][2] Share Repurchase and Capital Reduction - The cancellation of shares will reduce the company's registered capital by approximately 1.46 million yuan, representing 0.46% of the total share capital, which will decrease from 318 million shares to 316 million shares [2] - This action is part of the company's ongoing efforts to fulfill its repurchase commitments and enhance its equity structure, signaling confidence in its intrinsic value [2] Financial Performance - Haier Biomedical has shown steady growth since its establishment, with revenue increasing from 1.013 billion yuan in 2019 to 2.284 billion yuan in 2024, a growth rate of 125.47%, and net profit rising from 182 million yuan to 367 million yuan, a growth rate of 101.65% [3] - However, in the first three quarters of 2025, the company faced pressure, with revenue of 1.761 billion yuan, a year-on-year decline of 1.17%, and net profit of 198 million yuan, a decrease of 35.83% [3] - The third quarter of 2025 showed signs of recovery, with revenue of 566 million yuan, a year-on-year increase of 1.24% and a quarter-on-quarter increase of 11.68%, and net profit reaching 55.65 million yuan [3][4] R&D Investment and Technological Development - Over the past five years, Haier Biomedical has invested a total of 1.398 billion yuan in R&D, with annual expenditures ranging from 236 million yuan to 321 million yuan [5] - The company has established a multi-layer AI foundation and has led or participated in drafting 64 national and industry standards, with 32 recognized as internationally leading [5]

Group 1 - The company held its first extraordinary general meeting of shareholders on November 17, 2025, where it approved the election of Mr. Hu Xiangde as a non-independent director of the third board of directors [2] - The adjustment of the specialized committees of the board was also approved during the meeting, ensuring smooth operations following the changes in board membership [3] - The composition of the board's specialized committees was detailed, including the Strategic and ESG Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee [3] Group 2 - The company announced the cancellation of part of the repurchased shares and a reduction in registered capital, with 1,459,586 shares being adjusted from employee stock ownership plans to cancellation [11] - Following the cancellation, the total number of shares will decrease from 317,952,508 to 316,492,922, representing a reduction of 0.46% of the total share capital [14] - The company aims to enhance investor returns and maintain the interests of shareholders through this capital reduction [11][14]

Core Viewpoint - Haier Bio announced the election of Mr. Hu Xiangde, nominated by its major shareholder Qingdao Jiushi Investment Management Co., Ltd., as a non-independent director of the company's third board of directors [1] Company Summary - Haier Bio has agreed to elect Mr. Hu Xiangde as a non-independent director [1] - The nomination comes from Qingdao Jiushi Investment Management Co., Ltd., which holds more than 5% of the company's shares [1]

证券代码：688139 证券简称：海尔生物 公告编号：2025-059 青岛海尔生物医疗股份有限公司 关于完成补选董事及调整董事会专门委员会委员 的公告 青岛海尔生物医疗股份有限公司董事会 2025 年 11 月 17 日，公司召开第三届董事会第九次会议，审议通过了《关 于调整第三届董事会专门委员会委员的议案》，由于公司董事会成员发生变动， 为保证公司第三届董事会各专门委员会工作顺利开展，根据《公司法》和《公司 章程》的有关规定并结合公司实际情况，对第三届董事会专门委员会成员进行调 整，调整后公司第三届董事会专门委员会组成情况如下： 1、董事会战略与 ESG 委员会：谭丽霞女士（主任委员）、周云杰先生、刘 占杰先生、龚雯雯女士、陈洁女士、胡祥德先生、黄生先生（独立董事）、牛军 先生（独立董事）、许铭先生（独立董事） 2、董事会审计委员会：黄生先生（主任委员，独立董事）、陈洁女士、许 铭先生（独立董事） 3、董事会提名委员会：牛军先生（主任委员，独立董事）、刘占杰先生、 许铭先生（独立董事） 4、董事会薪酬与考核委员会：许铭先生（主任委员，独立董事）、谭丽霞 女士、黄生先生（独立董事） 特此公告。 本公司董事会 ...

青岛海尔生物医疗股份有限公司 关于注销部分回购股份并减少注册资本 暨通知债权人的公告 证券代码：688139 证券简称：海尔生物 公告编号：2025-058 公司债权人可持证明债权债务关系存在的合同、协议及其他凭证的原件及复 印件到公司申报债权。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、通知债权人的原因 青岛海尔生物医疗股份有限公司（以下简称"公司"、"海尔生物"）于 2025 年 10 月 30 日召开了第三届董事会第八次会议，并于 2025 年 11 月 17 日召 开了 2025 年第一次临时股东大会，分别审议通过了《关于变更部分回购股份用 途并注销暨减少注册资本的议案》，同意将存放于公司回购专用证券账户中的 1,459,586 股回购股份的用途进行调整，由"用于员工持股计划或股权激励"调 整为"用于注销并相应减少注册资本"。公司本次变更部分回购股份用途并注销 暨减少注册资本事项是为严格履行公司回购股份方案中关于回购股份使用期限 的相关承诺，同时增强投资者回报能力和水平，切实维护广大投资者利益。注销 完 ...

北京市金杜（青岛）律师事务所 关于青岛海尔生物医疗股份有限公司 2025 年第一次临时股东大会 之法律意见书 致：青岛海尔生物医疗股份有限公司 北京市金杜（青岛）律师事务所（以下简称本所）接受青岛海尔生物医疗 股份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简 称《证券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监 督管理委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民 共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特 别行政区、中国澳门特别行政区和中国台湾省）现行有效的法律、行政法规、 规章、规范性文件和现行有效的《青岛海尔生物医疗股份有限公司章程》（以下 简称《公司章程》）的有关规定，指派律师出席了公司于 2025 年 11 月 17 日召 开的 2025 年第一次临时股东大会（以下简称本次股东大会），并就本次股东大 会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限 于： 本所依据上述法律、行政法规、规章、规范性文件和《公司章程》的有关 规定以及本法律意见书出具日以前已经发生或者存在的 ...

证券代码：688139 证券简称：海尔生物 公告编号：2025-057 青岛海尔生物医疗股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法 承担法律责任。 本次会议由公司董事会召集，表决方式为现场投票与网络投票相结合的方式。 会议的召集、召开和表决方式符合《中华人民共和国公司法》《上海证券交易所 科创板股票上市规则》和《公司章程》的有关规定。公司董事长谭丽霞女士主持 现场会议。 （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事8人，出席8人； 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 17 日 （二） 股东大会召开的地点：青岛市高新区丰源路 280 号海尔生物医疗新兴产 业园办公楼 VIP 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 90 | | --- | --- | | 普通股股东人数 | ...

Core Viewpoint - Haier Biomedical announced the election of Liu Zhanjie as the employee representative director on the board, in compliance with the Company Law and the revised articles of association [1] Summary by Relevant Sections - **Board Composition**: The company’s board must include one employee director as per legal requirements [1] - **Election Process**: Liu Zhanjie was elected as the employee representative director through a workers' representative assembly [1] - **Announcement Reference**: Details regarding the board changes were disclosed in the announcement dated October 31 [1]